Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA1 | P23415 | 1/20 | 0.37 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.37 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5572486 | 0.73 | OR51E2 (0.30) | OR51E2 | |
| SCHEMBL16932997 | 0.73 | GLRA1 (0.35) | GLRA1SLC6A9OR51E2 | |
| SCHEMBL28639601 | 0.69 | TDP1 (0.37) | — | |
| SCHEMBL8640291 | 0.69 | CAMK2A (0.30) | — | |
| SCHEMBL5710710 | 0.67 | — | — | |
| SCHEMBL16245501 | 0.67 | GLRA1 (0.30) | GLRA1SLC6A9OR51E2MEN1LMNA | |
| SCHEMBL8812704 | 0.67 | LMNA (0.33) | OR51E2MEN1LMNAKMT2A | |
| SCHEMBL10923668 | 0.65 | ALDH1A1 (0.31) | — | |
| SCHEMBL4953695 | 0.65 | — | — | |
| SCHEMBL451714 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070410-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2012-03-22 | — | — | US | disclosed |
| WO-2010054058-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS AS MODULATORS OF PROTEIN KINASE | AMBIT BIOSCIENCE CORPORATION (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070410-A1 | IMIDAZOLOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | GRK2, GRK3, GRK4 | GLRA1 1139/4885SLC6A9 4649/4885OR51E2 3532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.